Rituximab combined to ACVBP (R-ACVBP) as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first-line.: Preliminary results on 119 patients of a GELA phase II study.

被引：2
|
作者：
Belhadi, Karim
Fitoussi, Olivier
Haioun, Corinne
Mounier, Nicolas
Lederlin, Pierre
Coiffier, Bertrand
Recher, Christian
Casasnovas, Olivier
Sebban, Catherine
Ferme, Christophe
Tilly, Herve
Gisselbrecht, Christian
机构：
[1] Hop Henri Mondor, Serv Hematol, F-94010 Creteil, France
[2] Polyclin Bordeuax Nord, Serv Oncol, Bordeaux, France
[3] Hop St Louis, Inst Hematol, Paris, France
[4] CHU Nancy Brabois, Serv Hematol, Vandoeuvre Les Nancy, France
[5] CHU Purpan, Serv Hematol, Toulouse, France
[6] CHU Dijon, Serv Hematol, Dijon, France
[7] Ctr Leon Berard, Serv Hematol, F-69373 Lyon, France
[8] Inst Gustave Roussy, Dept Med, Villejuif, France
[9] Ctr Henri Becquerel, Dept Hematol, F-76038 Rouen, France
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3049.3049
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3049
引用
收藏
页码：868A / 868A
页数：1
相关论文
共 50 条
  • [21] Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study
    Vitolo, Umberto
    Chiappella, Annalisa
    Angelucci, Emanuele
    Rossi, Giuseppe
    Liberati, Anna Marina
    Cabras, Maria Giuseppina
    Botto, Barbara
    Ciccone, Giovannino
    Gaidano, Gianluca
    Falchi, Lorenzo
    Freilone, Roberto
    Novero, Domenico
    Orsucci, Lorella
    Pavone, Vincenzo
    Pogliani, Enrico
    Rota-Scalabrini, Delia
    Salvi, Flavia
    Tonso, Anna
    Tucci, Alessandra
    Levis, Alessandro
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (09): : 1250 - 1258
  • [22] Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Haioun, C.
    Morschhauser, F.
    Jourdan, E.
    Karsenti, J.
    Hess, G.
    Duehrsen, U.
    Kravchenko, S.
    van Hal, G.
    Hahka-Kemppinen, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab Following Standard Chemotherapy for Patients with Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL) - Final Results
    Reddy, Nishitha M.
    Morgan, David S.
    Greer, John P.
    Chen, Heidi
    Park, Steven I.
    Richards, Kristy L.
    BLOOD, 2015, 126 (23)
  • [24] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation
    Bartlett, Nancy L.
    Chen, Andy I.
    Kolibaba, Kathryn S.
    Lamy, Thierry
    Jones, Surai
    Hirata, Jamie
    Sharman, Jeff P.
    BLOOD, 2015, 126 (23)
  • [25] HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST LINE TREATMENT FOR HIGH-RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB ERA: AN INTENTION TO TREAT-ANALYSIS
    Tisi, M. C.
    Maiolo, E.
    D'Alo, F.
    Bellesi, S.
    Sora, F.
    Chiusolo, P.
    Laurenti, L.
    Picardi, M.
    Alma, E.
    Larocca, L. M.
    Sica, S.
    Hohaus, S.
    HAEMATOLOGICA, 2014, 99 : 703 - 703
  • [26] Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: Updated results of the randomized LNH93-3 study.
    Reyes, F
    Lepage, E
    Morel, P
    Lederlin, P
    Coiffier, B
    Tilly, H
    Bosly, A
    Gabarre, J
    Briere, J
    Fillet, G
    Molina, T
    Gisselbrecht, C
    BLOOD, 1997, 90 (10) : 2640 - 2640
  • [27] Phase II Clinical Trial of R-CHOP Combined with Lenalidomide in the First-Line Treatment for Patients with High Risk Diffuse Large B Cell Lymphoma
    Zhao, Shuang
    Zhang, Jiuyang
    Yan, Zheng
    Xu, Yuanlin
    Yao, Zhihua
    Chu, Junfeng
    Yao, Shuna
    Wang, Haiying
    Zhou, Wenping
    Luo, Xufeng
    Zhang, Peipei
    Liu, Yanyan
    BLOOD, 2023, 142
  • [28] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
    Tilly, Herve
    Morschhauser, Franck
    Bartlett, Nancy L.
    Sharman, Jeff
    Haioun, Corinne
    Kolibaba, Kathryn S.
    Chen, Andy
    Lamy, Thierry
    Jones, Surai
    Penuel, Elicia
    Lee, Calvin
    Salles, Gilles A.
    BLOOD, 2016, 128 (22)
  • [29] Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).
    Bartlett, Nancy L.
    Farber, Charles M.
    Yasenchak, Christopher A.
    Ansell, Stephen Maxted
    Advani, Ranjana H.
    Knapp, Mark H.
    Fayad, Luis
    Kolibaba, Kathryn S.
    Patel-Donnelly, Dipti
    Seetharam, Mahesh
    Yimer, Habte Aragaw
    Manley, Thomas John
    Burke, John M.
    Holkova, Beata
    Budde, L. Elizabeth
    Halwani, Ahmad Sami
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage
    Toubai, Tomomi
    Kuroda, Junya
    Suehiro, Youko
    Mishima, Yuko
    Sunami, Kazutaka
    Kato, Koji
    Uoshima, Nobuhiko
    Kumode, Takahiro
    Ota, Ai
    Mitsuki, Kaori
    Yokota, Daisuke
    Sano, Yuri
    Terui, Yasuhito
    BLOOD, 2023, 142
12345